DPF

AstraZeneca’s diabetes drug “Farxiga” fails in Phase 3 trial for COVID-19 patients

Articles April 20 , 2021

Trial Results

In the global trial titled “DARE-19”, Farxiga (a diabetes drug produced by AstraZeneca) was given over 30 days to 1,250 patients hospitalized with COVID-19, along with the other standards of care.
“The trial did not achieve statistical significance for prevention of organ dysfunction and all-cause of COVID-19 mortality,” AstraZeneca said in a release.
The drug was administered to hospitalized patients who were vulnerable and at risk of developing serious COVID-19 symptoms.
Those that suffered from underlying conditions such as diabetes, hypertension, cardiovascular disease (ASCVD), heart failure or chronic kidney disease, or cardiac, renal, and metabolic comorbidities were the recipients of the drug.

“The Farxiga data did not achieve statistical significance in cutting the risk of the disease worsening and death in such patients, the Anglo-Swedish drugmaker said.” (1)

The company will present the full DARE-19 trial results at the American College of Cardiology Scientific Sessions in May 2021.